Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 301–400 of 1,001
D’Ascenzo, F., Biolè, C., Raposeiras‐Roubín, S., Gaido, F., Abu‐Assi, E., Kinnaird, T. D., Ariza‐Solé, A., Liebetrau, C., Manzano‐Fernández, S., Boccuzzi, G. G., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.10.001 · Cited by 42
Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
Tersalvi, G., Biasco, L., Cioffi, G. M., & Pedrazzini, G. B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072064 · Cited by 49
“Long-term therapy has been shown to mitigate the risk of subsequent ischemic events not only associated with culprit lesions/vessels, but also arising from the progression of atherosclerosis, also known as the “patient protective effect” [3,4].”
BackgroundResultAge- and sex-specific trends in the incidence of myocardial infarction in Denmark, 2005 to 2021
Christensen, D. M., Strange, J. E., Phelps, M. D., Schjerning, A. M., Sehested, T. S. G., Gerds, T. A., & Gislason, G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.03.003 · Cited by 47
Ito, S., Watanabe, H., Morimoto, T., Yoshikawa, Y., Shiomi, H., Shizuta, S., Ono, K., Yamaji, K., Soga, Y., Hyodo, M., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.02.010 · Cited by 42
Buccheri, S., Capodanno, D., James, S. K., & Angiolillo, D. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1680637 · Cited by 42
“Prolonged DAPT has been identified as one important determinants of excess bleeding with antiplatelet therapy [69,94].”
BackgroundMehran, R., Chandrasekhar, J., Urban, P. M., Lang, I. M., Windhövel, U., Spaulding, C. M., Copt, S., Stoll, H., Morice, M., & for the LEADERS FREE Investigators (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0285 · Cited by 41
Patient-tailored antithrombotic therapy following percutaneous coronary intervention
van der Sangen, N. M. R., Rozemeijer, R., Yin, D. R. P. P. C. P., Valgimigli, M., Windecker, S., James, S. K., Buccheri, S., ten Berg, J. M., Henriques, J. P. S., Voskuil, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1097 · Cited by 42
“22 Overall, at 30months after index PCI, there was a trend towards increased all-cause mortality (0.5% absolute increase) with extended DAPT, explained by a statistically significant increase in non-cardiovascular mortality, mainly attributed to increased cancer related mortality.”
InfluentialDual antiplatelet therapy: optimal timing, management, and duration
Sabouret, P. F., Rushton-Smith, S. K., Kernéis, M., Silvain, J., Collet, J., & Montalescot, G. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv015 · Cited by 40
Bohula, E. A., Aylward, P. E., Bonaca, M. P., Corbalan, R. L., Kiss, R. G., Murphy, S. A., Scirica, B. M., White, H., Braunwald, E., & Morrow, D. A. (2015) · Circulation · doi:10.1161/circulationaha.114.015042 · Cited by 38
“The addition of more potent antiplatelet therapy to aspirin via P2Y12 adenosine diphosphate (ADP) receptor inhibition resulted in a reduction in recurrent cardiovascular events when used for at least one year following an acute coronary syndrome (ACS) or for at least 30 months following percutaneous coronary intervent…”
MethodSelf-citationAbtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Reid, C. M., Baumgärtner, I., Wu, D., Hanson, M. E., Hannachi, H., et al. (2017) · Clinical Cardiology · doi:10.1002/clc.22721 · Cited by 42
“Therapy Study) trial showed clear benefit of prolonged dual antiplatelet therapy in PAD patients treated with coronary stents.(39) Recently, vorapaxar, a PAR1 platelet receptor antagonist has been evaluated in addition to aspirin in the TRA 2 P –TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atheroth…”
MethodSelf-citationPlanning secondary prevention: Room for improvement
Beringola, A. C., Fitzsimons, D., Pelliccia, A., Moreno, G., Martín‐Asenjo, R., & Bueno, H. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317704954 · Cited by 45
Eight-year follow-up of the Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) trial
Hage, A., Voisine, P., Erthal, F., Larose, É., Glineur, D., Chow, B. J. W., Tremblay, H., Fortier, J. H., Ko, G., Une, D., et al. (2017) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.06.039 · Cited by 40
“In this regard, most studies so far have focused on the efficacy of DAPT during the first year after intervention, both in interventional cardiology and in cardiac surgery.(8,10,12,13) Very few subsequent, long-term data exist, to which we believe that our study contributes significantly.”
BackgroundBeiswenger, A. C., Jo, A., Harth, K. C., Kumins, N. H., Shishehbor, M. H., & Kashyap, V. S. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.02.047 · Cited by 40
Verheugt, F. W. A., ten Berg, J. M., Storey, R. F., Cuisset, T., & Granger, C. B. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.080 · Cited by 41
Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation
Capodanno, D., Gargiulo, G., Buccheri, S., Giacoppo, D., Capranzano, P., & Tamburino, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.085 · Cited by 40
“The observed significant link between bleeding and noncardiovascular mortality is consistent with a pattern already noted in the DAPT trial, where bleedingrelated, trauma-related, and cancer-related causes primarily contributed to the observed higher risk of all-cause mortality with prolonged DAPT (3).”
ResultInfluentialDellborg, M., Bonaca, M. P., Storey, R. F., Steg, P. G., Im, K. A., Cohen, M. C., Bhatt, D. L., Ophuis, T. O., Budaj, A., Hamm, C. W., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz020 · Cited by 39
Self-citationD’Ascenzo, F., Bertaina, M., Fioravanti, F., Bongiovanni, F., Raposeiras‐Roubín, S., Abu‐Assi, E., Kinnaird, T. D., Ariza‐Solé, A., Manzano‐Fernández, S., Templin, C., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319836327 · Cited by 39
“The American College of Cardiology/American Heart Association guidelines suggest using the ‘DAPT Score’ for decision making.(29,30) Among the proposed indicators, presentation with an acute MI, as well as a history of MI, are considered as risk factors for recurrent ischaemic events.”
MethodSelf-citationMadhavan, M. V., Redfors, B., Ali, Z. A., Prasad, M., Shahim, B., Smits, P. C., von Birgelen, C., Zhang, Z., Mehran, R., Serruys, P. W. J. C., et al. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008565 · Cited by 39
Kim, W., Mun, J.-Y., Baek, S.-W., Kim, M., Yang, G., Jeong, M.-S., Choi, S. Y., Han, J.-Y., Kim, M. H., & Leem, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179596 · Cited by 39
“In addition, since these purinergic antiplatelet agents are often used as a dual therapy in combination with aspirin in the clinic [10], the co-treatment effects with these agents and aspirin were compared for cell invasion.”
BackgroundResultUpdate on antithrombotic therapy after percutaneous coronary revascularisation
Cuisset, T., Verheugt, F. W. A., & Mauri, L. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31936-0 · Cited by 42
Self-citationMechanistic Insights to Target Atherosclerosis Residual Risk
Alkhalil, M. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.06.004 · Cited by 39
Yang, S., Kang, J., Park, K. W., Hur, S., Lee, N. H., Hwang, D., Yang, H., Ahn, H., Cha, K. S., Jo, S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.031 · Cited by 38
Antiplatelet therapy in acute coronary syndromes
Grove, E. L., Würtz, M., Thomas, M. R., & Kristensen, S. D. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1079619 · Cited by 39
“Recent data showed that prolonged DAPT beyond 1 year after stent placement in patients with ACS or stable angina significantly reduced the risk of stent thrombosis and MI when treated for 30 months instead of 12 months [102].”
BackgroundGulizia, M. M., Colivicchi, F., Abrignani, M. G., Ambrosetti, M., Aspromonte, N., Barile, G., Caporale, R., Casolo, G., Chiuini, E., Lenarda, A. D., et al. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy019 · Cited by 39
Antithrombotic Agents and Cancer
Bruno, A., Dovizio, M., Tacconelli, S., Contursi, A., Ballerini, P., & Patrignani, P. (2018) · Cancers · doi:10.3390/cancers10080253 · Cited by 39
Moalem, K., Baber, U., Chandrasekhar, J., Claessen, B. E. P. M., Sartori, S., Aquino, M. B., Dangas, G., Iakovou, I. P., Colombo, A., Kini, A., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1392-2 · Cited by 38
Self-citationThe Two-way Relationship Between Cancer and Atherosclerosis
Raposeiras‐Roubín, S., & Cordero, A. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2018.12.010 · Cited by 40
Chandiramani, R., Cao, D., Claessen, B. E. P. M., Sorrentino, S., Guedeney, P., Blum, M., Goel, R., Roumeliotis, A., Krucoff, M. W., Kozuma, K., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014611 · Cited by 38
“23,24 There are no prior data on sex-based long-term outcomes following PCI specifically in the HBR population with which the present results may be compared.”
Self-citationCollet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 46
Strom, J. B., Faridi, K. F., Butala, N. M., Zhao, Y., Tamez, H., Valsdottir, L. R., Brennan, J. M., Shen, C., Popma, J. J., Kazi, D. S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046159 · Cited by 37
Self-citationMeta-Analysis of Long-Term Clinical Outcomes of Everolimus-Eluting Stents
Toyota, T., Shiomi, H., Morimoto, T., & Kimura, T. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.03.059 · Cited by 37
Fanari, Z., Malodiya, A., Weiss, S. A., Hammami, S., Kolm, P., & Weintraub, W. S. (2017) · Cardiovascular Revascularization Medicine · doi:10.1016/j.carrev.2016.07.006 · Cited by 36
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Adamski, P., Adamska, U., Ostrowska, M., Koziński, M., & Kubica, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241234 · Cited by 37
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents
Stuckey, T., Kirtane, A. J., Brodie, B. R., Witzenbichler, B., Litherland, C., Weisz, G., Rinaldi, M., Neumann, F., Metzger, D. C., Henry, T. D., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.05.059 · Cited by 38
“randomized to an additional 18 months of DAPT versus ASA alone after 12 months had reduced rates of ST and MI at the cost of increased bleeding and possibly mortality (6).”
Self-citationElmariah, S., Doros, G. D., Benavente, O., Bhatt, D. L., Connolly, S. J., Yusuf, S., Steinhubl, S. R., Liu, Y., Hsieh, W.-H., Yeh, R. W., et al. (2018) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.117.005795 · Cited by 39
Self-citationLindholm, D. P., James, S. K., Bertilsson, M., Becker, R. C., Cannon, C. P., Giannitsis, E., Harrington, R. A., Himmelmänn, A., Kontny, F. P., Siegbahn, A., et al. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.261271 · Cited by 37
Self-citationPiccolo, R., Magnani, G., Ariotti, S., Gargiulo, G., Marino, M., Santucci, A., Franzone, A., Tebaldi, M., Heg, D., Windecker, S., et al. (2017) · EuroIntervention · doi:10.4244/eij-d-16-00497 · Cited by 37
Rivaroxaban in Peripheral Artery Disease after Revascularization
Ultee, K. H. J., Steunenberg, S. L., & Schouten, O. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2030413 · Cited by 37
Scirica, B. M., Bergmark, B. A., Morrow, D. A., Antman, E. M., Bonaca, M. P., Murphy, S. A., Sabatine, M. S., Braunwald, E., & Wiviott, S. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.067 · Cited by 36
Self-citationMechanically Robust Plasma-Activated Interfaces Optimized for Vascular Stent Applications
Santos, M., Filipe, E. C., Michael, P. L., Hung, J., Wise, S. G., & Bilek, M. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b01279 · Cited by 40
Westman, P. C., Lipinski, M. J., Torguson, R., & Waksman, R. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.10.005 · Cited by 39
Sun, J., Shi, A., Tong, Z., & Xue, W. (2017) · World Journal of Urology · doi:10.1007/s00345-017-2129-y · Cited by 36
“A prolonged DAPT use was recommended to reduce mortality and stent thrombosis [23, 24].”
BackgroundLong-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54
Parker, W. A., & Storey, R. F. (2016) · Heart · doi:10.1136/heartjnl-2015-307858 · Cited by 36
Povsic, T. J., Roe, M. T., Ohman, E. M., Steg, P. G., James, S. K., Plotnikov, A. N., Mundl, H., Welsh, R. C., Bode, C., & Gibson, C. M. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.004 · Cited by 36
Self-citationA comparative study on in vitro degradation behavior of PLLA-based copolymer monofilaments
Shi, D., Kang, Y., Zhang, G., Gao, C., Lu, W. J., Yang, C., Zou, H. H., & Jiang, H. (2018) · Polymer Degradation and Stability · doi:10.1016/j.polymdegradstab.2018.11.005 · Cited by 35
Muramatsu, T., Masuda, S., Kotoku, N., Kozuma, K., Kawashima, H., Ishibashi, Y., Nakazawa, G., Takahashi, K., Okamura, T., Miyazaki, Y., et al. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0051 · Cited by 35
Trends in Cardiovascular Medicine
(2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(03)00104-x · Cited by 35
Fanaroff, A. C., Hasselblad, V., Roe, M. T., Bhatt, D. L., James, S. K., Steg, P. G., Gibson, C. M., & Ohman, E. M. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.046 · Cited by 34
Self-citationHowell, S. J., Hoeks, S. E., West, R. M., Wheatcroft, S. B., Hoeft, A., Leva, B., Plichon, B., Damster, S., Momeni, M., Watremez, C., et al. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.09.029 · Cited by 34
Kerkmeijer, L. S. M., Renkens, M. P. L., Tijssen, R. T., Hofma, S. H., van der Schaaf, R. J., Arkenbout, E. K., Weevers, A. W., Garcia-Garcia, H. G.-G., Kraak, R. P., Piek, J. J., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00419 · Cited by 34
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 48
Valgimigli, M., Ariotti, S., & Costa, F. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv053 · Cited by 34
Thukkani, A. K., Agrawal, K., Prince, L., Smoot, K. J., Dufour, A. B., Cho, K., GAGNON, D. R., Sokolovskaya, G., Ly, S., Temiyasathit, S., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1339 · Cited by 33
Individualizing Medicinal Therapy Post Heart Stent Implantation: Tailoring for Patient Factors
Mohamad, T. N., Jyotsna, F., Farooq, U., Fatima, A., Kar, I., Khuwaja, S., Memon, U. A., Kumari, V., Puri, P., Aslam, Z. M., et al. (2023) · Cureus · doi:10.7759/cureus.43977 · Cited by 40
Musumeci, G., Lettieri, C., Limbruno, U., Senni, M., Guagliumi, G., Valsecchi, O., Angiolillo, D., Rossini, R., & Capodanno, D. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1057 · Cited by 33
“The observed increase in ischaemic events in our study could be the reflection of a withdrawal of protection arising from antiplatelet discontinuation, whereas a rebound effect cannot be excluded in view of recent data from a large randomised study showing an early catch up in ST and ischaemic events during the early…”
ResultInterventional Options for Coronary Artery Calcification
Tomey, M. I., & Sharma, S. K. (2016) · Current Cardiology Reports · doi:10.1007/s11886-015-0691-8 · Cited by 34
Gargiulo, G., Ariotti, S., Santucci, A., Piccolo, R., Baldo, A., Franzone, A., Magnani, G., Marino, M., Esposito, G., Windecker, S., et al. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.05.046 · Cited by 33
Toyota, T., Shiomi, H., Morimoto, T., Natsuaki, M., & Kimura, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174502 · Cited by 33
Староверов, И. И., Shakhnovich, R. M., Gilyarov, M. Y., Komarov, A. L., Константинова, Е. В., Панченко, Е. П., & Yavelov, I. S. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-1-4-77 · Cited by 35
Lee, A. T., Gagnidze, A., Pan, S. R., Sookplung, P., Nair, B. G., Newman, S.-F., Ben-Ari, A. Y., Zaky, A., Cain, K., Vavilala, M. S., et al. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002053 · Cited by 33
Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease
Lettino, M., Leonardi, S., Maria, E. D., & Halvorsen, S. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317707854 · Cited by 32
“A first trial of long-term DAPT with aspirin and clopidogrel versus aspirin alone in a broad population of patients with risk factors or prior atherothrombotic diseases did not show a statistically significant benefit of DAPT.”
MethodInfluentialHernández, J. M. D. L. T., & Edelman, E. R. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.07.008 · Cited by 32
Strom, J. B., Tamez, H. E., Zhao, Y., Valsdottir, L. R., Curtis, J. P., Brennan, J. M., Shen, C., Popma, J. J., Mauri, L., & Yeh, R. W. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.02.007 · Cited by 32
Self-citationA Comprehensive Update on Aspirin Management During Noncardiac Surgery
Gerstein, N. S., Albrechtsen, C. L., Mercado, N. F., Cigarroa, J. E., & Schulman, P. M. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005064 · Cited by 35
Parvar, S., Ngo, L., Dawson, J. A., Nicholls, S. J., Fitridge, R., Psaltis, P. J., & Ranasinghe, I. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab116 · Cited by 32
Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis
Mavrakanas, T. A., Chatzizisis, Y. S., Gariani, K., Kereiakes, D. J., Gargiulo, G., Helft, G., Gilard, M., Feres, F., da Costa, R. A., Morice, M., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12901018 · Cited by 33
Self-citationPosition Statement on Antiplatelet Therapy for East Asians With Coronary Artery Disease
Gong, Y., Jeong, Y., Wang, T., Tan, J. W. C., Qian, J., Yan, H., Chan, M. Y., Chen, Y., Zhang, S., Yuan, Z., et al. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.04.010 · Cited by 32
Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction
Cohen, M. C. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1227-1 · Cited by 31
“The DAPT study investigated the incidence of stent thrombosis and major cardiovascular and cerebrovascular events (a composite of death, MI, or stroke) in patients who had received a stent [46].”
BackgroundUpdate on primary PCI for patients with STEMI
Thomas, M. P., & Bates, E. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.06.010 · Cited by 31
“[37] Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al.”
BackgroundPedroza, C., Tyson, J. E., Das, A., Laptook, A. R., Bell, E. F., & Shankaran, S. (2016) · Trials · doi:10.1186/s13063-016-1480-4 · Cited by 31
Grodecki, K., Huczek, Z., Ścisło, P., Kowara, M., Raposeiras‐Roubín, S., D’Ascenzo, F., Abu‐Assi, E., Henriques, J. P. S., Saucedo, J., González‐Juanatey, J. R., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.022 · Cited by 31
Butala, N. M., Faridi, K. F., Tamez, H. E., Strom, J. B., Song, Y., Shen, C., Secemsky, E. A., Mauri, L., Kereiakes, D. J., Curtis, J. P., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056878 · Cited by 35
Self-citationNatsuaki, M., Sonoda, S., Yoshioka, G., Hongo, H., Kaneko, T., Kashiyama, K., Yokoi, K., Hikichi, Y., & Node, K. (2022) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-022-00847-1 · Cited by 34
“Prolonged DAPT prevents ischemic events after coronary stenting, but increases bleeding [7].”
BackgroundScott, S. A., Collet, J. ‐., Baber, U., Yang, Y., Peter, I., Linderman, M. D., Sload, J., Qiao, W., Kini, A. S., Sharma, S., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.401 · Cited by 31
The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease
Nathan, A. S., Sen, S., & Yeh, R. W. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1315101 · Cited by 31
Self-citationCortese, B., Pellegrini, D., Latini, R. A., Palma, G. D., Perotto, A., & Orrego, P. S. (2019) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000806 · Cited by 31
Mehran, R., Giustino, G., & Baber, U. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.024 · Cited by 31
“These results must be interpreted within the context of the recently completed, large DAPT trial (17).”
ResultTherapeutic angiogenesis based on injectable hydrogel for protein delivery in ischemic heart disease
Wang, J., Song, Y., Xie, W., Zhao, J., Wang, Y., & Yu, W. (2023) · iScience · doi:10.1016/j.isci.2023.106577 · Cited by 32
“Traditional treatment strategies include drug therapy, such as antiplatelet drugs, lipid-lowering drugs, drugs to reduce myocardial oxygen consumption, thrombolytic drugs, percutaneous transluminal coronary intervention, and surgical bypass grafting.(5,6) However, some patientsmaynotbe suitable for traditional treatme…”
BackgroundGe, F., Lin, H., Liu, Y., Li, M., Guo, R., Ruan, Z., & Chang, T. (2016) · European Journal of Neurology · doi:10.1111/ene.12982 · Cited by 33
Kim, T., Kim, C. H., Kang, S., Ban, S. P., & Kwon, O.-K. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.05.071 · Cited by 31
Faridi, K. F., Tamez, H. E., Butala, N. M., Song, Y., Shen, C., Secemsky, E. A., Mauri, L., Curtis, J. P., Strom, J. B., & Yeh, R. W. (2021) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006589 · Cited by 30
Self-citationKeykhaei, M., Ashraf, H., Rashedi, S., Farrokhpour, H., Heidari, B., Zokaei, S., Bagheri, S., Foroumadi, R., Asgarian, S., Amirian, A., et al. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00976-7 · Cited by 37
Meyer, B. M., Campos, J. K., de Beaufort, J. C. C., Chen, I., Khan, M., Amin, G., Zarrin, D., Lien, B. V., & Coon, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11082234 · Cited by 30
5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent
Yeh, R. W., Silber, S., Chen, L., Chen, S., Hiremath, S., Neumann, F., Qiao, S., Saito, S., Xu, B., Yang, Y., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.11.004 · Cited by 30
Self-citationReintroduction of anti‐thrombotic therapy after a gastrointestinal haemorrhage: if and when?
Scott, M. J., Veitch, A., & Thachil, J. V. (2017) · British Journal of Haematology · doi:10.1111/bjh.14599 · Cited by 30
“Although this only equates to a small absolute increase in risk of 0 12% per year (McQuaid & Laine, 2006), considering that aspirin users number in the tens of millions, 35% of whom will be elderly, this small absolute risk translates to a significant overall effect on the incidence of GIH…”
BackgroundCost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction
Magnuson, E. A., Li, H., Wang, K., Vilain, K. R., Shafiq, A., Bonaca, M. P., Bhatt, D. L., Cohen, M. C., Steg, P. G., Storey, R. F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.05.063 · Cited by 30
Self-citationSiddiqi, O. K., Smoot, K. J., Dufour, A. B., Cho, K., Young, M., GAGNON, D. R., Ly, S., Temiyasathit, S., Faxon, D. P., Gaziano, J. M., et al. (2015) · Heart · doi:10.1136/heartjnl-2014-307168 · Cited by 29
Roe, M. T., Cyr, D. D., Eckart, D., Schulte, P. J., Morse, M. A., Blackwell, K., Ready, N., Zafar, S. Y., Beaven, A., Strickler, J. H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv611 · Cited by 29
Self-citationFaggioni, M., Baber, U., Sartori, S., Giustino, G., Cohen, D. J., Henry, T. D., Farhan, S., Ariti, C. A., Dangas, G., Gibson, C. M., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.12.003 · Cited by 31
Self-citationBlin, P., Dureau‐Pournin, C., Lassalle, R., Jové, J., Thomas‐Delecourt, F., Droz‐Perroteau, C., Danchin, N., & Moore, N. D. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13291 · Cited by 29
“Some studies seem to indicate no added benefit beyond one year, others that there may be a benefit beyond one year DAPT or that stopping DAPT may be associated with increased risk.[2-8] Most of these studies were of clopidogrel, a pro-drug with many potential interactions that may reduce its benefits.”
BackgroundInhibition of high shear arterial thrombosis by charged nanoparticles
Griffin, M. T., Zhu, Y., Liu, Z. L., Aidun, C. K., & Ku, D. N. (2018) · Biomicrofluidics · doi:10.1063/1.5025349 · Cited by 29
Berry, N. C., Mauri, L., Steg, P. G., Bhatt, D. L., Hohnloser, S. H., Nordaby, M., Miede, C., Kimura, T., Lip, G. Y. H., Oldgren, J., et al. (2020) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008349 · Cited by 31
Self-citationIwasaki, Y., Koike, J., Ko, T., Funatsu, A., Kobayashi, T., Ikeda, T., & Nakamura, S. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01684-z · Cited by 29
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial
Sidhu, M. S., Alexander, K. P., Huang, Z., O’Brien, S. M., CHAITMAN, B. R., Stone, G. W., Newman, J. D., Boden, W. E., Maggioni, A. P., Steg, P. G., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.01.017 · Cited by 30
Self-citationSabouret, P. F., Lemesle, G., Bellemain-Appaix, A., Aubry, P., Bocchino, P.-P., Rafflenbeul, E., Belle, L., Nolan, J., Bernardi, M., Biondi‐Zoccai, G., et al. (2022) · Archives of Medical Science · doi:10.5114/aoms/150321 · Cited by 32
“The DAPT study [33], which compared 30 versus 12 months of DAPT (clopidogrel or prasugrel), supports longer-term use of DAPT beyond 12 months to reduce the risk of ischaemic events and stent thrombosis, but with an increased risk of bleeding and an increase of non-cardiovascular death and total mortality which has not…”
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54
Bonaca, M. P., Im, K., Magnani, G., Bansilal, S., Dellborg, M., Storey, R. F., Bhatt, D. L., Steg, P. G., Cohen, M. C., Johanson, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac402 · Cited by 30
Self-citationTitanium-nitride-oxide-coated coronary stents: insights from the available evidence
Karjalainen, P. P., & Nammas, W. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1244353 · Cited by 29
“complications, compared with aspirin alone (66).”
Goodman, S. G., Nicolau, J. C., Requena, G., Maguire, A., Blankenberg, S., Chen, J. Y., Granger, C. B., Grieve, R., Pocock, S., Simon, T., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.062 · Cited by 29
Secemsky, E. A., Yeh, R. W., Kereiakes, D. J., Cutlip, D. E., Cohen, D. J., Steg, P. G., Cannon, C. P., Apruzzese, P. K., D’Agostino, R. B., Massaro, J. M., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0063 · Cited by 29
Self-citationBare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015?
Meraj, P., Jauhar, R., & Singh, A. (2015) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-015-0393-y · Cited by 29
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.